FDA Approves First-in-Class RAS Inhibitor Daraxonrasib for Metastatic Pancreatic Cancer

Adults with previously treated metastatic pancreatic cancer now have access to a daily pill that nearly doubles their median survival time compared to standard chemotherapy, fundamentally altering the prognosis for one of the deadliest malignancies. The U.S. Food and Drug Administration officially approved daraxonrasib, marketed under the brand name Rasonque, on August 26, 2026. This regulatory clearance marks the first time a targeted therapy has successfully inhibited the RAS genetic pathway, a biological mechanism that drives the vast majority of pancreatic tumors but has historically evaded pharmacological intervention. The approval introduces a highly effective, less toxic alternative for patients whose disease has progressed after initial systemic treatments.[6]

More than 90 percent of pancreatic ductal adenocarcinomas are fueled by mutations in the KRAS oncogene, a critical member of the broader RAS family of genes. In a healthy cell, these proteins regulate normal growth, but when mutated, they act as a stuck switch that continuously signals the cell to divide and multiply out of control. While oncologists and molecular biologists have understood this mechanism for decades, the physical structure of the RAS protein made it notoriously difficult to target. Its smooth, spherical surface offered no obvious deep pockets or crevices where traditional small-molecule drugs could securely bind, earning the protein a long-standing reputation in the pharmaceutical industry as entirely "undruggable."[1][4][6]

Daraxonrasib bypasses this historical structural challenge by employing a novel mechanism of action known as a molecular glue. Rather than attempting to wedge into a non-existent pocket on the RAS protein itself, the drug binds to the active, or "ON," state of the RAS protein alongside another naturally occurring cellular protein called cyclophilin A. This unique tri-complex formation effectively neutralizes the abnormal growth signals and halts tumor progression. Crucially, because of its broad mechanism, daraxonrasib is capable of inhibiting a wide range of RAS mutations simultaneously, rather than being restricted to a single specific genetic variant like earlier generations of targeted therapies.[3][4]

The FDA's decision was driven by definitive efficacy data from the phase 3 RASolute 302 clinical trial, a massive international effort that enrolled 500 patients across 59 clinical sites in North America, Europe, and Asia. Every participant in the trial had metastatic pancreatic cancer that had already progressed after at least one initial round of standard systemic therapy. When researchers compared the outcomes directly against the investigator's choice of standard intravenous chemotherapy, the results were stark: patients receiving the daily daraxonrasib pill lived a median of 13.2 months, compared to just 6.7 months for the chemotherapy control group, representing a 60 percent reduction in the risk of death.[6]

The trial's lead investigator, Dr. Brian Wolpin, who serves as the director of the Hale Family Center for Pancreatic Cancer Research at the Dana-Farber Cancer Institute, characterized the clinical results as a fundamental and long-awaited shift for the oncology field. "The FDA approval of daraxonrasib represents a landmark advance for patients with metastatic pancreatic cancer," Wolpin stated in a press release following the regulatory announcement. "The nearly doubling of median overall survival time seen with this targeted treatment represents meaningful progress for patients where new treatment options are urgently needed."[1]

Beyond the primary endpoint of overall survival, the RASolute 302 trial demonstrated that daraxonrasib significantly improved both progression-free survival and objective response rates, meaning patients were far more likely to see their tumors shrink or stop growing entirely. Furthermore, patients taking the oral medication experienced a substantially more favorable safety profile than those subjected to the systemic toxicity of traditional chemotherapy. The most common adverse effects reported during the trial were dermatological rashes, mouth inflammation, mild nausea, and diarrhea, which were generally manageable with supportive care and led to significantly fewer permanent treatment discontinuations.[4][6]

Recognizing the urgent clinical need in a disease space that has seen very few major breakthroughs, the FDA authorized the drug approximately six and a half months ahead of its scheduled statutory goal date. The application was processed under the agency's National Priority Review Voucher pilot program, a specialized regulatory pathway designed to accelerate the review of medical products that address critical national health priorities. Prior to the final approval, daraxonrasib had also received both breakthrough therapy and orphan drug designations, underscoring the severe lack of effective second-line treatments for metastatic pancreatic adenocarcinoma.[6]

The successful deployment of a pan-RAS inhibitor in pancreatic cancer is already prompting aggressive investigations into its potential efficacy for other RAS-driven malignancies across the body. Early-phase clinical trials are currently evaluating daraxonrasib in metastatic lung cancer and colorectal cancer, where researchers are optimistic that its ability to target multiple KRAS variants simultaneously will offer similar, unprecedented survival advantages. For the immediate future, the pancreatic cancer medical community is focused on rapidly integrating the newly approved oral therapy into standard clinical practice, ensuring equitable access, and monitoring long-term patient outcomes as the drug reaches the broader public.[3][7]